Anti-alpha-galactosyl antibody (Anti-Gal)

The anti-alpha-galactosyl (anti-Gal) antibody is the most abundant naturally occurring antibody in humans, apes, and Old World monkeys, comprising approximately 1% of total circulating immunoglobulins [1, 3]. It specifically recognizes the alpha-gal epitope (Gal-alpha-1,3-Gal-beta-1,4-GlcNAc-R), a carbohydrate structure synthesized by non-primate mammals but absent in humans due to the evolutionary inactivation of the GGTA1 gene [2, 4, 11]. In clinical medicine, anti-Gal is best known as the primary immunological barrier in xenotransplantation, where it binds to porcine tissues and triggers hyperacute rejection through complement activation [5, 12, 14]. Beyond its role in rejection, the antibody is strategically harnessed in cancer immunotherapy and vaccine development to opsonize tumor cells or antigens, thereby facilitating their uptake by antigen-presenting cells via Fc-gamma receptor interactions [1, 5, 8]. Conversely, the production of anti-Gal IgE antibodies—often induced by tick bites—leads to alpha-gal syndrome, a serious allergic condition characterized by delayed hypersensitivity to red meat and immediate anaphylactic reactions to alpha-gal-containing pharmaceuticals [13, 16, 20]. Ongoing research also investigates the use of alpha-gal-functionalized nanoparticles to recruit macrophages for accelerated wound healing and tissue regeneration [3, 6].

Other names

Natural anti-Gal antibodyAnti-alpha-gal antibodyAnti-Galili antibodyAnti-Gal IgGAnti-alpha-galactosyl IgG/IgM/IgE

The antibody binds to alpha-gal epitopes expressed on the surface of targets (such as modified tumor cells, antigens, or xenografts), subsequently triggering the classical complement pathway or facilitating opsonization and recruitment of antigen-presenting cells via Fc-gamma receptor (FcγR) binding [1, 5, 14].